Advanced Search

Preplanned Studies: A Multi-Regional Epidemiological Evaluation on Post-vaccination Serological Testing in Prevention of Vertical Transmission of Hepatitis B Virus — 10 Counties, 5 Provinces, China, 2019–2024

View author affiliations
  • Summary

    What is already known about this topic?

    Post-vaccination serologic testing (PVST) of infants born to hepatitis B virus (HBV) infected mothers is important for evaluating effectiveness of strategies for preventing mother-to-child transmission (MTCT) of HBV.

    What is added by this report?

    PVST was conducted in 43.7% of 7,425 infants born to HBV-infected mothers and showed that 0.8% of infants had breakthrough infections, indicating a very low level of prevention failure; anti-HBs positivity was 97.0% showing vaccine-induced protection; and 2.2% of HBV-exposed infants needed revaccination. Prevention failure was 12.7-fold higher among infants born to HBeAg-positive mothers.

    What are the implications for public health practice?

    MTCT prevention strategy is highly effective. PVST evaluates MTCT prevention strategy and identifies infants needing revaccination; its use should be increased. Findings support WHO’s HBV elimination strategy.

  • loading...
  • Conflicts of interest: No conflicts of interest declared by any authors.
  • Funding: The study was funded by the Major Science and Technology Special Project of China’s 13th 5-Year Plan (grant no.2017ZX10105015)
  • [1] Kyuregyan KK, Kichatova VS, Isaeva OV, Potemkin IA, Malinnikova EY, Lopatukhina MA, et al. Coverage with timely administered vaccination against hepatitis B virus and its influence on the prevalence of HBV infection in the regions of different endemicity. Vaccines 2021;9(2):82. https://doi.org/10.3390/vaccines9020082.
    [2] World Health Organization. Hepatitis B. 2024. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. [2025-3-20].
    [3] Miao N, Wang FZ, Zheng H, Yin ZD, Zhang GM. Hepatitis B vaccine coverage and factors influencing coverage among children 1-14 years of age in China in 2020. Chin J Vaccines Immun 2022;28(6):679 − 83. https://doi.org/10.19914/j.CJVI.2022125.
    [4] Zheng H, Wang Y, Wang FZ, Shen LP, Zhang GM, Liu JH, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. Lancet Reg Health West Pac 2024;51:101193. https://doi.org/10.1016/j.lanwpc.2024.101193.
    [5] Lu QB, Cui F. Preventing mother-to-child transmission of HBV. Lancet Infect Dis 2022;22(8):1096 − 7. https://doi.org/10.1016/S1473-3099(22)00216-X.
    [6] World Health Organization. Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec 2017;92(27):369-92. https://www.who.int/publications/i/item/WER9227.
    [7] Wang FZ, Zhang GM, Zheng H, Miao N, Shen LP, Wang F, et al. Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China. Vaccine 2017;35(33):4229 − 35. https://doi.org/10.1016/j.vaccine.2017.06.019.
    [8] Zhou Y, Lu ZJ, He HQ, Yan R, Deng X, Tang XW, et al. Influencing factors and necessity of post-vaccination serologic testing follow-up for HBsAg-positive mothers and their infants: a 5-year prospective study in Zhejiang Province, China (2016-2020). J Viral Hepat 2021;28(10):1413 − 21. https://doi.org/10.1111/jvh.13581.
    [9] Wang W, Luo YL, Tang WP, Chen JH, Wang LL. Current status of post-vaccination serological test after children born among HBsAg-positive mothers in Baoan District of Shenzhen City. Chin J Health Educ 2021;37(10):880 − 3. https://doi.org/10.16168/j.cnki.issn.1002-9982.2021.10.004.
    [10] Schillie S, Walker T, Veselsky S, Crowley S, Dusek C, Lazaroff J, et al. Outcomes of infants born to women infected with hepatitis B. Pediatrics 2015;135(5):e1141 − 7. https://doi.org/10.1542/peds.2014-3213.
    [11] Lu Y, Song YR, Zhai XJ, Zhu FC, Liu JX, Chang ZJ, et al. Maternal hepatitis B e antigen can be an indicator for antiviral prophylaxis of perinatal transmission of hepatitis B virus. Emerg Microbes Infect 2021;10(1):555 − 64. https://doi.org/10.1080/22221751.2021.1899055.
    [12] Boucheron P, Lu Y, Yoshida K, Zhao TS, Funk AL, Lunel-Fabiani F, et al. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis 2021;21(1):85 − 96. https://doi.org/10.1016/S1473-3099(20)30593-4.
    [13] Qin W, Wang Y, Zhang XQ, Pan F, Cheng K, Sui HT, et al. A retrospective study of hepatitis B vaccination in preterm birth and low birth weight infants born to hepatitis B surface antigen-positive mothers: time to close the policy-practice gap. Hum Vaccin Immunother 2022;18(7):2155390. https://doi.org/10.1080/21645515.2022.2155390.
    [14] Deng K, Liang J, Mu Y, Liu Z, Wang YP, Li MR, et al. Preterm births in China between 2012 and 2018: an observational study of more than 9 million women. Lancet Glob Health 2021;9(9):e1226 − 41. https://doi.org/10.1016/S2214-109X(21)00298-9.
    [15] Soans S, Mihalyi A, Berlaimont V, Kolhapure S, Dash R, Agrawal A. Vaccination in preterm and low birth weight infants in India. Hum Vaccin Immunother 2022;18(1):1 − 12. https://doi.org/10.1080/21645515.2020.1866950.
    [16] Hofstetter AM, Jacobson EN, deHart MP, Englund JA. Early childhood vaccination status of preterm infants. Pediatrics 2019;144(3):e20183520. https://doi.org/10.1542/peds.2018-3520.
    [17] Ijaz S, Derrick J, Shute J, Ireland G, Hayden I, Ngui SL, et al. Mother to infant transmission of hepatitis B virus in the face of neonatal immunization is not necessarily primary vaccine failure. Clin Infect Dis 2022;74(7):1151 − 7. https://doi.org/10.1093/cid/ciab622.
    [18] Yin XR, Han GR, Zhang H, Wang M, Zhang WJ, Gao YF, et al. A real-world prospective study of mother-to-child transmission of HBV in China using a mobile health application (Shield 01). J Clin Transl Hepatol 2020;8(1):1 − 8. https://doi.org/10.14218/JCTH.2019.00057.
  • TABLE 1.  Timely co-administration (HepB1 + HBIG1) and full-course vaccination in infants born to HBsAg+ mothers, 2019–2024.

    Variable No. observed (N=7,425, %) Timely co-administration
    (HepB1 + HBIG1)
    Full-course vaccination
    with HepB
    No. observed
    (N=7,041)
    Rate (%) No. observed
    (N=7,386)
    Rate (%)
    Province
    Zhejiang 496 (6.7) 472 95.2 489 98.6
    Fujian 4,087 (55.0) 3,930 96.2 4,072 99.6
    Henan 1,141 (15.4) 1,006 88.1 1,139 99.8
    Sichuan 993 (13.4) 973 98.0 989 99.6
    Gansu 708 (9.5) 660 93.2 697 98.5
    Maternal age (years)
    15–24 436 (5.9) 411 94.3 433 99.3
    25–29 2,238 (30.1) 2,107 94.1 2,221 99.2
    30–34 3,119 (42.0) 2,970 95.2 3,104 99.5
    35–50 1,632 (22.0) 1,553 95.2 1,628 99.8
    Ethnicity
    Han 7,099 (95.6) 6,725 94.7 7,060 99.5
    Other 326 (4.4) 316 96.9 326 100.0
    Maternal education
    Junior high school and below 5,299 (71.4) 5012 94.6 5,271 99.5
    High school and above 2,125 (28.6) 2,028 95.4 2,114 99.5
    Maternal occupation
    Farmer 1,475 (19.9) 1,374 93.2 1,470 99.7
    Other 5,950 (80.1) 5,667 95.2 5,916 99.4
    HBV infected time (y)
    ≤5 3,412 (46.0) 3,219 94.3 3,393 99.4
    >5 4,013 (54.0) 3,822 95.2 3,993 99.5
    Maternal receipt of HBV DNA tested
    Yes 842 (11.4) 820 97.4 835 99.2
    No 6,568 (88.6) 6,209 94.5 6,537 99.5
    Maternal receipt of antiviral therapy during pregnancy
    Yes 386 (5.2) 373 96.6 383 99.2
    No 7,038 (94.8) 6,667 94.7 7,002 99.5
    Maternal HBeAg status during pregnancy
    Negative 5,582 (75.2) 5,295 94.9 5,558 99.6
    Positive 1,675 (22.6) 1,594 95.2 1,663 99.3
    Unknown 166 (2.2) 150 90.4 163 98.2
    Infant sex
    Male 3,958 (53.3) 3,758 94.9 3,936 99.4
    Female 3,463 (46.7) 3,281 94.7 3,446 99.5
    Birth weight (kg)
    ≥2.50 7,198 (97.0) 6,839 95.0 7,164 99.5
    <2.50 225 (3.0) 201 89.3 220 97.8
    Pregnancy duration (weeks)
    ≥37 7,022 (94.6) 6,687 95.2 6,987 99.5
    <37 401 (5.4) 353 88.0 397 99.0
    Maternal parity
    1 2,105 (28.4) 1,986 94.4 2,096 99.6
    2 3,936 (53.0) 3,753 95.4 3,916 99.5
    ≥3 1,381 (18.6) 1,301 94.2 1,371 99.3
    Mode of delivery
    Vaginal delivery 3,942 (53.1) 3,717 94.3 3,917 99.4
    Caesarean section 3,482 (46.9) 3,323 95.4 3,468 99.6
    Abbreviation: HBV=hepatis B virus; DNA=deoxyribonucleic acid; HBeAg=hepatis B e-antigen; HepB1 + HBIG1=first dose of hepatitis B vaccine plus hepatitis B immunoglobulin; HepB=hepatitis B vaccine.
    Download: CSV

    TABLE 2.  Maternal characteristics, HBsAg and HBsAb positivity in infants, and associated risk factors based on PVST results..

    Variable No. with PVST (N=3,243) HBsAg status HBsAb status
    No. positive
    (N=26)
    Rate (%) No. positive
    (N=3,147)
    Rate (%)
    Maternal age (years)*
    15–24 215 2 0.9 210 97.7
    25–29 963 14 1.4 928 96.4
    30–34 1,340 6 0.5 1,299 96.9
    35–50 725 4 0.6 710 97.9
    Maternal ethnicity
    Han 3,115 25 0.8 3,024 97.1
    Other 128 1 0.8 123 96.1
    Maternal education
    Junior high school and below 2,187 13 0.6 2,117 96.8
    High school and above 1,056 13 1.2 1,030 97.5
    Maternal occupation
    Farmers 881 9 1.0 840 95.3
    Other 2,362 17 0.7 2,307 97.7
    HBV infected time (years)
    ≤5 1,410 9 0.6 1,373 97.4
    >5 1,833 17 0.9 1,774 96.8
    Maternal HBV DNA tested
    Yes 469 4 0.9 462 98.5
    No 2,761 22 0.8 2,672 96.8
    Maternal receipt of antiviral therapy during pregnancy
    Yes 202 2 1.0 197 97.5
    No 3,040 24 0.8 2,949 97.0
    Maternal HBeAg status during pregnancy*
    Negative 2,420 5 0.2 2,370 97.9
    Positive 745 19 2.6 704 94.5
    Unknown 77 2 2.6 72 93.5
    Received HBIG during pregnancy
    Yes 41 1 2.4 40 97.6
    No 2,950 24 0.8 2,860 97.0
    Unknown 248 1 0.4 243 98.0
    Infant sex
    Male 1,687 15 0.9 1,639 97.2
    Female 1,554 11 0.7 1,506 96.9
    Birth weight (kg)
    ≥2.50 3,121 26 0.8 3,025 96.9
    <2.50 120 0 0.0 120 100
    Pregnancy duration (weeks)
    ≥37 3,058 26 0.9 2,965 97.0
    <37 183 0 0.0 180 98.4
    Maternal parity
    1 1,042 10 1.0 1,011 97.0
    2 1,646 13 0.8 1,599 97.1
    ≥3 552 3 0.5 534 96.7
    Mode of delivery
    Vaginal delivery 1,639 14 0.9 1,598 97.5
    Caesarean section 1,603 12 0.8 1,548 96.6
    Timely receipt of HBIG
    No 60 1 1.7 59 98.3
    Yes 3,183 25 0.8 3,088 97.0
    Timely receipt of first HepB dose
    No 181 3 1.7 176 97.2
    Yes 3,062 23 0.8   2,971 97.0
    Univariate analysis results: * HbsAg group: P<0.05; HBsAb group: P<0.05.
    Abbreviation: PVST=post vaccination serological testing; HBV=hepatis B virus; DNA=deoxyribonucleic acid; HBsAg=hepatitis B surface antigen; HBsAb=hepatitis B surface antibody; HepB=hepatitis B vaccine; HBIG=hepatitis B immunoglobulin; HBeAg=hepatitis B e-antigen.
    Download: CSV

Citation:

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Turn off MathJax
Article Contents

Article Metrics

Article views(288) PDF downloads(1) Cited by()

Share

Related

A Multi-Regional Epidemiological Evaluation on Post-vaccination Serological Testing in Prevention of Vertical Transmission of Hepatitis B Virus — 10 Counties, 5 Provinces, China, 2019–2024

View author affiliations

Summary

What is already known about this topic?

Post-vaccination serologic testing (PVST) of infants born to hepatitis B virus (HBV) infected mothers is important for evaluating effectiveness of strategies for preventing mother-to-child transmission (MTCT) of HBV.

What is added by this report?

PVST was conducted in 43.7% of 7,425 infants born to HBV-infected mothers and showed that 0.8% of infants had breakthrough infections, indicating a very low level of prevention failure; anti-HBs positivity was 97.0% showing vaccine-induced protection; and 2.2% of HBV-exposed infants needed revaccination. Prevention failure was 12.7-fold higher among infants born to HBeAg-positive mothers.

What are the implications for public health practice?

MTCT prevention strategy is highly effective. PVST evaluates MTCT prevention strategy and identifies infants needing revaccination; its use should be increased. Findings support WHO’s HBV elimination strategy.

  • 1. National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
  • 2. Department of National Immunization Program, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan Province, China
  • 3. Department of National Immunization Program, Fujian Provincial Center for Disease Control and Prevention, Fuzhou City, Fujian Province, China
  • 4. Department of National Immunization Program, Gansu Provincial Center for Disease Control and Prevention, Lanzhou City, Gansu Province, China
  • 5. Department of National Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou City, Zhejiang Province, China
  • 6. Department of National Immunization Program, Sichuan Provincial Center for Disease Control and Prevention, Chengdu City, Sichuan Province, China
  • Corresponding author:

    Fuzhen Wang, wangfz@chinacdc.cn

  • Funding: The study was funded by the Major Science and Technology Special Project of China’s 13th 5-Year Plan (grant no.2017ZX10105015)
  • Online Date: May 09 2025
    Issue Date: May 09 2025
    doi: 10.46234/ccdcw2025.108
    • Introduction: Infants born to HBsAg-positive mothers are exposed to hepatitis B virus (HBV) during childbirth and require timely hepatitis B vaccination (HepB) and hepatitis B immunoglobulin (HBIG) to prevent vertical transmission. Post-vaccination serological testing (PVST) determines whether HBV-exposed infants are protected, infected, or need revaccination. This study evaluated PVST implementation among HBV-exposed infants and the effectiveness of the recommended strategy to prevent mother-to-child transmission (MTCT) of HBV.

      Methods: This observational study of infants born to HBsAg-positive mothers evaluated implementation of the MTCT prevention strategy and PVST follow-up across five provinces in China. Chi-square tests assessed timely HepB1 and HBIG administration and HepB series completion. PVST was used to evaluate MTCT prevention effectiveness. Bivariate analyses explored factors influencing infection and protection rates among HBV-exposed infants.

      Results: Among 7,425 infants born to HBsAg-positive mothers, 94.8% received timely HepB1 and HBIG, and 99.5% completed the full HepB vaccination series. PVST was conducted in 3,243 (43.7%) infants; the median interval between HepB3 and PVST was 66 days (interquartile range: 47–114). 26 (0.8%) infants tested HBsAg-positive; 3,147 (97.0%) developed protective antibody levels; and 72 (2.2%) were neither infected nor protected, requiring revaccination. Maternal HBeAg positivity was a significant risk factor for MTCT prevention failure [adjusted odds ratio (aOR)=12.7, 95% confidence interval (CI): 4.7, 34.1].

      Conclusions: The MTCT prevention strategy was highly effective. PVST for infants born to HBsAg-positive mothers enables evaluation of MTCT prevention strategies and improvement of strategy their effectiveness. PVST utilization should be expanded to test all HBV-exposed infants to ensure their protection and to further enhance the MTCT prevention.

    • Timely administration of a birth dose of hepatitis B vaccine (HepB) is critically important for preventing hepatitis B virus (HBV) infection by preventing vertical transmission of HBV during childbirth (1). According to the World Health Organization (WHO), the prevalence of chronic HBV infection among children under five years of age declined from approximately 5% in the pre-vaccine era (1980s to early 2000s) to below 1% in 2019 (2). In China, the HepB immunization schedule provides the first dose (HepB1) within 24 hours of birth, followed by second (HepB2) and third (HepB3) doses at 1 and 6 months of age. The National Viral Hepatitis Prevention and Control Plan (2017–2020) set targets to maintain timely HepB1 coverage >90% and full-series coverage (HepB3) >95%. A 2020 nationally-representative survey found that among 1–4-year-old children, 91.54% received HepB1 ≤24 hours after birth and 99.21% completed HepB3. Among 1–14-year-old children, corresponding rates were 89.05% and 98.46%, indicating high ultimate coverage but persistent gaps in timely HepB1 administration (3). Universal HepB vaccination significantly reduced hepatitis B infection among children and adolescents. The 2020 national HBV seroepidemiological survey shoewd dramatic declines in hepatitis B surface antigen (HBsAg) prevalence, from 9.67% (in 1992) to 0.30% in children aged 1–4 years, and from 10.74% to 0.94% in 5–14-year-old (4).

      The WHO’s 2030 goal to eliminate viral hepatitis as a major public health threat has an objective to achieve an HBsAg seroprevalence of ≤0.1% among children under five years old. Preventing mother-to-child transmission (MTCT) of HBV during childbirth is essential to achieve this objective. Co-administration of hepatitis B immunoglobulin (HBIG) with HepB1 enhances MTCT prevention efficacy (5). China’s Guidelines for the Prevention and Treatment of Chronic Hepatitis B and the National Immunization Program Schedule for Children (2021 Edition) emphasize administering HepB1 and HBIG within 12 hours of birth to newborns of HBsAg-positive mothers (6). Post-vaccination serological testing (PVST) is used to determine the effectiveness of MTCT prevention in infants. PVST assesses HBsAg and anti-HBs antibody levels at 9–12 months of age or 1–2 months after vaccine series completion.

      We evaluated timeliness of HepB vaccination and effectiveness of MTCT prevention strategies in children born during 2019–2024 in pilot counties/districts with established PVST surveillance. We determined factors associated with MTCT prevention failure and assessed impact of the current strategy, with an aim to provide evidence-based recommendations for optimizing MTCT prevention.

      The study was conducted in selected counties across five provinces in China: Zhejiang (Jinyun and Suichang counties), Fujian (Shishi City and Huian County), Henan (Yuanyang and Sui counties, and Huaiyang District), Sichuan (Dujiangyan City and Lu County), and Gansu (Ganzhou District and Tongwei County). Study subjects included infants born to HBsAg-positive mothers during 2019–2024 and their mothers. Data collection encompassed demographics, prenatal HBV screening results, use of antiviral therapy during pregnancy, maternal HBIG use, delivery details, administration of HepB1, HBIG, and HepB3, PVST results, and HepB revaccination if indicated by PVST. Data were obtained from maternal and child health (MCH) institutions (information on mothers, pregnancies, deliveries, and HepB1 and HBIG administration), vaccination clinics (HepB2 and HepB3 data), and MCH laboratories (PVST results).

      Infant-level outcomes were defined as: 1) PVST utilization: testing blood for HBsAg and HBsAb; 2) MTCT prevention success: HBsAg-negative and HBsAb-positive; 3) HBV infection: HBsAg-positive; 4) HBV susceptibility: HBsAg-negative and HBsAb-negative; 5) timely co-administration of HepB1+HBIG: HepB1 administered ≤24 hours and HBIG1 ≤12 hours after birth; and 6) timely completion of HepB3.

      Statistical analysis was performed using Microsoft Excel 2019 (Microsoft Corp., Redmond, WA, USA) and SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Descriptive statistics were used to summarize baseline characteristics. Outcomes are reported as proportions with 95% confidence intervals (CI). Chi-square tests (α=0.05, two-tailed) were used for univariate analysis, while multivariate analysis was conducted using unconditional logistic regression (α=0.05, two-tailed).

      Table 1 shows characteristics of the subjects: 7,425 HBsAg-positive mothers and their liveborn, HBV-exposed infants. The mean maternal age was 31.19±4.39 years. Among these infants, 7,041 (94.8%) received timely HepB1 and HBIG co-administration, and 7,386 (99.5%) completed the HepB3 series. Among the infant subjects, 3,243 (43.7%) underwent post-vaccination serologic testing. The median interval between HepB3 administration and PVST was 66 days (interquartile range: 47–114). Of the infants with PVST, 26 (0.8%) were HBsAg-positive,indicating breakthrough infection. HBsAg positivity decreased by year from 1.7% in 2019 to 0.3% in 2023. Additionally, 3,147 (97.0%) infants were anti-HBs-positive, indicating vaccine-induced protection, while 72 (2.2%) infants tested negative for both HBsAg and anti-HBs and required revaccination. No significant difference in maternal HBeAg status was observed between infants with PVST (22.2% HBeAg+) and those without PVST(23.0% HBeAg+) (P=0.56) (Supplementary Table S1).

      Variable No. observed (N=7,425, %) Timely co-administration
      (HepB1 + HBIG1)
      Full-course vaccination
      with HepB
      No. observed
      (N=7,041)
      Rate (%) No. observed
      (N=7,386)
      Rate (%)
      Province
      Zhejiang 496 (6.7) 472 95.2 489 98.6
      Fujian 4,087 (55.0) 3,930 96.2 4,072 99.6
      Henan 1,141 (15.4) 1,006 88.1 1,139 99.8
      Sichuan 993 (13.4) 973 98.0 989 99.6
      Gansu 708 (9.5) 660 93.2 697 98.5
      Maternal age (years)
      15–24 436 (5.9) 411 94.3 433 99.3
      25–29 2,238 (30.1) 2,107 94.1 2,221 99.2
      30–34 3,119 (42.0) 2,970 95.2 3,104 99.5
      35–50 1,632 (22.0) 1,553 95.2 1,628 99.8
      Ethnicity
      Han 7,099 (95.6) 6,725 94.7 7,060 99.5
      Other 326 (4.4) 316 96.9 326 100.0
      Maternal education
      Junior high school and below 5,299 (71.4) 5012 94.6 5,271 99.5
      High school and above 2,125 (28.6) 2,028 95.4 2,114 99.5
      Maternal occupation
      Farmer 1,475 (19.9) 1,374 93.2 1,470 99.7
      Other 5,950 (80.1) 5,667 95.2 5,916 99.4
      HBV infected time (y)
      ≤5 3,412 (46.0) 3,219 94.3 3,393 99.4
      >5 4,013 (54.0) 3,822 95.2 3,993 99.5
      Maternal receipt of HBV DNA tested
      Yes 842 (11.4) 820 97.4 835 99.2
      No 6,568 (88.6) 6,209 94.5 6,537 99.5
      Maternal receipt of antiviral therapy during pregnancy
      Yes 386 (5.2) 373 96.6 383 99.2
      No 7,038 (94.8) 6,667 94.7 7,002 99.5
      Maternal HBeAg status during pregnancy
      Negative 5,582 (75.2) 5,295 94.9 5,558 99.6
      Positive 1,675 (22.6) 1,594 95.2 1,663 99.3
      Unknown 166 (2.2) 150 90.4 163 98.2
      Infant sex
      Male 3,958 (53.3) 3,758 94.9 3,936 99.4
      Female 3,463 (46.7) 3,281 94.7 3,446 99.5
      Birth weight (kg)
      ≥2.50 7,198 (97.0) 6,839 95.0 7,164 99.5
      <2.50 225 (3.0) 201 89.3 220 97.8
      Pregnancy duration (weeks)
      ≥37 7,022 (94.6) 6,687 95.2 6,987 99.5
      <37 401 (5.4) 353 88.0 397 99.0
      Maternal parity
      1 2,105 (28.4) 1,986 94.4 2,096 99.6
      2 3,936 (53.0) 3,753 95.4 3,916 99.5
      ≥3 1,381 (18.6) 1,301 94.2 1,371 99.3
      Mode of delivery
      Vaginal delivery 3,942 (53.1) 3,717 94.3 3,917 99.4
      Caesarean section 3,482 (46.9) 3,323 95.4 3,468 99.6
      Abbreviation: HBV=hepatis B virus; DNA=deoxyribonucleic acid; HBeAg=hepatis B e-antigen; HepB1 + HBIG1=first dose of hepatitis B vaccine plus hepatitis B immunoglobulin; HepB=hepatitis B vaccine.

      Table 1.  Timely co-administration (HepB1 + HBIG1) and full-course vaccination in infants born to HBsAg+ mothers, 2019–2024.

      Table 2 shows univariate analyses of HBsAg-positivity (MTCT prevention failure) and HBsAb positivity in infants by demographic, maternal, and delivery characteristics. There were significant differences in HBsAg positivity by maternal age and HBeAg status. There were significant differences in HBsAb positivity by maternal occupation, maternal HBV DNA testing, and receipt of HBIG during pregnancy (P<0.05). In multivariate logistic regression, maternal HBeAg-positivity was significantly associated with infant HBsAg-positivity (aOR=12.7, 95% CI: 4.7, 34.1).

      Variable No. with PVST (N=3,243) HBsAg status HBsAb status
      No. positive
      (N=26)
      Rate (%) No. positive
      (N=3,147)
      Rate (%)
      Maternal age (years)*
      15–24 215 2 0.9 210 97.7
      25–29 963 14 1.4 928 96.4
      30–34 1,340 6 0.5 1,299 96.9
      35–50 725 4 0.6 710 97.9
      Maternal ethnicity
      Han 3,115 25 0.8 3,024 97.1
      Other 128 1 0.8 123 96.1
      Maternal education
      Junior high school and below 2,187 13 0.6 2,117 96.8
      High school and above 1,056 13 1.2 1,030 97.5
      Maternal occupation
      Farmers 881 9 1.0 840 95.3
      Other 2,362 17 0.7 2,307 97.7
      HBV infected time (years)
      ≤5 1,410 9 0.6 1,373 97.4
      >5 1,833 17 0.9 1,774 96.8
      Maternal HBV DNA tested
      Yes 469 4 0.9 462 98.5
      No 2,761 22 0.8 2,672 96.8
      Maternal receipt of antiviral therapy during pregnancy
      Yes 202 2 1.0 197 97.5
      No 3,040 24 0.8 2,949 97.0
      Maternal HBeAg status during pregnancy*
      Negative 2,420 5 0.2 2,370 97.9
      Positive 745 19 2.6 704 94.5
      Unknown 77 2 2.6 72 93.5
      Received HBIG during pregnancy
      Yes 41 1 2.4 40 97.6
      No 2,950 24 0.8 2,860 97.0
      Unknown 248 1 0.4 243 98.0
      Infant sex
      Male 1,687 15 0.9 1,639 97.2
      Female 1,554 11 0.7 1,506 96.9
      Birth weight (kg)
      ≥2.50 3,121 26 0.8 3,025 96.9
      <2.50 120 0 0.0 120 100
      Pregnancy duration (weeks)
      ≥37 3,058 26 0.9 2,965 97.0
      <37 183 0 0.0 180 98.4
      Maternal parity
      1 1,042 10 1.0 1,011 97.0
      2 1,646 13 0.8 1,599 97.1
      ≥3 552 3 0.5 534 96.7
      Mode of delivery
      Vaginal delivery 1,639 14 0.9 1,598 97.5
      Caesarean section 1,603 12 0.8 1,548 96.6
      Timely receipt of HBIG
      No 60 1 1.7 59 98.3
      Yes 3,183 25 0.8 3,088 97.0
      Timely receipt of first HepB dose
      No 181 3 1.7 176 97.2
      Yes 3,062 23 0.8   2,971 97.0
      Univariate analysis results: * HbsAg group: P<0.05; HBsAb group: P<0.05.
      Abbreviation: PVST=post vaccination serological testing; HBV=hepatis B virus; DNA=deoxyribonucleic acid; HBsAg=hepatitis B surface antigen; HBsAb=hepatitis B surface antibody; HepB=hepatitis B vaccine; HBIG=hepatitis B immunoglobulin; HBeAg=hepatitis B e-antigen.

      Table 2.  Maternal characteristics, HBsAg and HBsAb positivity in infants, and associated risk factors based on PVST results..

    • This real-world study evaluated the effectiveness of the current HepB vaccine- and HBIG-based strategy for preventing mother-to-child transmission of HBV during childbirth. Based on post-vaccination serologic testing of HBV-exposed infants, we found an exceptionally low prevention strategy failure rate of 0.8%. Vaccination induced protective antibody levels in 97.0% of HBV-exposed infants, while the remaining 2.2% were neither infected nor protected, requiring revaccination to ensure protection. The PVST utilization rate was 43.7% among these HBV-exposed infants, and the 66-day median interval between the last dose of HepB vaccine and PVST was appropriate for accurate test results. Our findings strongly support the HepB vaccine- and HBIG-based strategy for prevention of vertical transmission and demonstrate the importance of increasing PVST utilization among HBV-exposed infants in China.

      The 43.7% PVST rate we observed is lower than previously reported PVST follow-up rates in China. A retrospective study in Jilin, Henan, Sichuan, and Gansu provinces found a PVST rate of 66% (7). Zhejiang Province (2016–2020) and Bao’an District in Shenzhen City, Guangdong Province (2017–2019) reported PVST rates of 67% (8) and 54% (9), respectively. The suboptimal PVST compliance rate and wide provincial variation we identified highlight a critical gap in monitoring MTCT prevention strategies and underscore the need for improved adherence to PVST protocols.

      The MTCT prevention failure rate of 0.8% that we found is slightly lower than the 1.1% rate in the USA (10) and the 3.7% rate reported in a four-province study (11), but slightly higher than the 0.77% rate observed in Zhejiang Province (8), suggesting regional variation in implementation of HBV MTCT prevention measures. HBeAg positivity was a significant risk factor for breakthrough infection, consistent with other studies (7,11), reinforcing the importance of prenatal HBV serological screening to identify high-risk pregnancies (12).

      Encouragingly, 97.0% of HBV-exposed infants developed protective hepatitis B surface antibody (anti-HBs), providing likely lifelong protection from HBV infection. This finding was similar to the 97% anti-HBs seropositivity reported in Zhejiang (8). PVST effectively identifies infants who remain susceptible to HBV and need revaccination. Our finding that 2.2% of vaccinated HBV-exposed infants required revaccination is consistent with reported HepB vaccine non-response rates of 2.6%–10% (12).

      Our study demonstrated high adherence to the WHO-recommended passive-active immunization protocol (HepB1 + HBIG1 within 24 hours of birth), with 95% timely HBIG1 administration and 95% timely co-administration of HepB1 and HBIG. Preterm infants had lower co-administration rates (89.33% vs. 95.01% in term infants) (13), consistent with findings from Anhui Province. China’s rising preterm birth rate (14) poses a challenge to MTCT prevention (15-16).

      Maternal antenatal interventions, including HBV DNA testing (14.46%) and antiviral therapy (6.23%), were underutilized. Among the 26 HBsAg-positive infants, 22 and 24 were born to mothers who did not receive DNA testing or antiviral treatment during pregnancy, respectively. Antiviral therapy in HBsAg-positive mothers with high viral loads reduces intrauterine and perinatal transmission risk (17-18). Limited access to HBV DNA testing in rural healthcare facilities may contribute to this gap (8), underscoring the need to strengthen prenatal screening and treatment infrastructure.

      This study was subject to at least two limitations. Missing data on the exact timing of HepB1 administration (i.e., <12 or <24 hours after birth) precluded evaluating strategy effectiveness with a first dose timing at shorter intervals within the first day of life. The number of breakthrough infections was too small to determine factors associated with breakthrough infection other than maternal HBeAg status. For example, there were too few breakthrough infections to evaluate shorter time frames for administration of HepB1 and HBIG. Because HBV DNA testing was not standard of care, we were unable to analyze breakthrough infections by quantitative DNA analysis. Future research with larger study populations is needed to address these limitations.

      In conclusion, the MTCT prevention strategy in China is highly effective, with only 0.8% of infants born to HBV-infected mothers experiencing breakthrough infections. PVST monitoring for children born to HBsAg-positive mothers enables collection of MTCT prevention data and evaluation of revaccination effectiveness in HBV-exposed infants, enhancing HBV MTCT prevention. However, PVST is underutilized, and PVST compliance rates vary by province. We recommend strengthening training and supervision of PVST to increase use of properly conducted PVST in China. Evaluation of PVST results is critically important to strengthen the HBV MTCT prevention strategy and to evaluate progress toward WHO’s target of 0.1% HBsAg prevalence among all children five years and under.

    • This study was approved by the Ethics Committee of the China CDC (Approval number: 201837).

  • Conflicts of interest: No conflicts of interest declared by any authors.
  • Reference (18)

    Citation:

    Catalog

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return